Press releases
- Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
- Charles River Laboratories Announces Second-Quarter 2022 Results
- Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
- Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
- Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
- Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
- Charles River Laboratories to Participate in Jefferies and William Blair Conferences
More ▼
Key statistics
On Friday, Charles River Laboratories International Inc (RV6:STU) closed at 223.65, 16.27% above the 52 week low of 192.36 set on Jun 20, 2022.
52-week range
Markit short selling activity
Open | 217.75 |
---|---|
High | 223.65 |
Low | 217.75 |
Bid | 225.90 |
Offer | 228.15 |
Previous close | 216.35 |
Average volume | 9.27 |
---|---|
Shares outstanding | 50.86m |
Free float | 50.35m |
P/E (TTM) | 26.29 |
Market cap | 11.52bn USD |
EPS (TTM) | 8.62 USD |
Data delayed at least 15 minutes, as of Aug 12 2022.
More ▼